Hyperprolactinemia is a major cause of infertility, brought about by inhibition of gonadotropin-releasing hormone (GnRH) secretion from the hypothalamus and impairment of luteinizing hormone (LH) output from the pituitary gland. However, whereas the actions of prolactin (PRL) within the brain have been investigated extensively, its specific effects at the level of pituitary gonadotroph target cells remain unclear. Here, we provide evidence that the actions of PRL within the gonadotroph are more complex than originally envisaged. Using a gonadotroph cell monoculture, the first series of experiments showed that PRL is, paradoxically, a potent stimulator of LH release, with a three-to fourfold increase in LH values at hyperprolactinemic concentrations of PRL. Conversely, PRL dose-dependently modulated the LH secretory response to GnRH in a biphasic manner, with classical suppression of LH output only detected under a narrow dose range. In contrast, at all doses tested, PRL blocked the LHB mRNA response to the secretagogue. Subsequent studies revealed that the stimulatory effects of PRL on LH release are not mediated by the conventional cytokine receptor pathways but, rather, by a novel JAK2-PIK3-PKC-dependent signaling cascade. Moreover, the experiments showed that these actions of PRL within gonadotroph cells are controlled by dopamine, the main hypothalamic inhibitory regulator of PRL release in vivo. Our findings have unraveled specific actions of PRL within the gonadotroph and the cellsignaling interactions that ultimately underlie hyperprolactinemia-induced infertility.
INTRODUCTION
Hyperprolactinemia is an important cause of infertility, brought about by inhibition of the reproductive axis at two anatomically distinct sites. Indeed, in addition to the suppressive actions of prolactin (PRL) on the secretion of gonadotropin-releasing hormone (GnRH) from neurons in the hypothalamus [1] [2] [3] , a direct effect of PRL at the level of the pituitary gland on the gonadotropic axis is also apparent in both males and females. In the female rat, lactational hyperprolactinemia decreased the luteinizing hormone (LH) response to exogenous GnRH in vivo [4] , and exogenous PRL administration reduced the proportion of pituitary gonadotroph cells [5] and suppressed both basal and GnRH-stimulated LH release from pituitary fragments [6] . In the male rat, experimentally induced hyperprolactinemia decreased not only the postcastration rise in LH but also the LH response to GnRH in gonadal intact animals [7] . Notably, studies by our group have shown that in ovine and equine primary pituitary cell cultures, PRL suppresses the LH response to GnRH only when applied concomitantly with bromocriptine (Br), a dopamine (DA) agonist [8, 9] . Moreover, in the ovine pituitary, the PRL receptor (PRLR) is selectively expressed in the gonadotroph [10] , and in the LbT2 gonadotroph cell line, the expression of both the PRLR and DA-2 receptor (DRD2) has been documented [11, 12] . Therefore, PRL and DA can act directly at the level of the gonadotroph to evoke their effects. However, whereas the cellular and molecular effects of DA in the gonadotroph are reasonably well defined [11, 13] , those of PRL are not.
Due to a lack of inherent kinase activity, the PRLR is coupled to janus kinase 2 (JAK2). Binding of a PRL molecule leads to dimerization of the receptor, phosphorylation of the JAK2 proteins located on both intercellular chains, and phosphorylation of the receptor itself [14] . This phosphorylation step is followed by the binding of a signal transducer and activator of transcription (STAT) protein, which dissociates once it has been phosphorylated by JAK2 [15] . In the brain, STAT5 is specifically activated by binding of PRL to the PRLR [16] [17] [18] . Following phosphorylation, STAT5 proteins dimerize and bind specific nuclear DNA-binding motifs to suppress or activate gene transcription [19] . PRL has also been shown to signal via the mitogen-activated protein kinase (MAPK) pathway and specifically activate MAPK3 and MAPK1 (previously known as ERK1 and ERK2, respectively) [20, 21] . Since the STAT5 and MAPK pathways are associated with nuclear and transcriptional actions, they may play a role in mediating any effects of PRL on LHB mRNA synthesis.
In many cell types, calcium is the major determinant of hormone release [22] , and to our knowledge, the STAT5 and MAPK cascades have not been shown to directly affect intracellular calcium. However, the activation of protein kinase C (PKC) by PRL has been described in isolated hepatocyte nuclei [23] . This enzyme is able to increase the sensitivity of calcium for exocytosis [24] , and its activation or inhibition may account for any affects of PRL on LH release. Therefore, it is feasible that any effects of PRL on LH release are mediated by PKC.
The LbT2 gonadotroph cell line is a useful tool with which to study the effects of PRL and DA on the gonadotroph, because it expresses the necessary receptors, synthesizes LHB mRNA, and secretes LH in response to GnRH [25] . Nonetheless, it could be argued that endocrine cells in the developing and adult pituitary gland are arranged into threedimensional networks, unlike LbT2 cells, which form a twodimensional matrix, and that the arrangement of endocrine cells into these networks has important implications for the coordinated propagation of cell-cell information, spatiotemporal control of signaling pathway activation, and hormone release [26] . However, the cell line represents a homogeneous population of gonadotrophs, devoid of the physical and humoral-mediated heterogeneous cell-cell interactions, thus making the true effects of PRL upon neuroendocrine target cells difficult to interpret when using primary cultures or whole-organ explants. Therefore, to investigate the specific action of PRL upon the gonadotroph, we assessed the effects of PRL and DA on basal and GnRH-stimulated LH synthesis and release, investigated the signaling pathways utilized by PRL, and characterized the interactions between PRL and GnRH in LbT2 gonadotroph cell monocultures.
MATERIALS AND METHODS

Cell Culture and Materials
All experiments used LbT2 gonadotroph cells, kindly donated by Dr. P.L. Mellon (University of California, San Diego). Cells were cultured as previously described [12] . Briefly, cells were grown on six-well plates in Dulbecco modified Eagle medium (DMEM), 10% fetal calf serum, and 1% penicillin/ streptomycin under humidified conditions at 378C and 5% CO 2 . Once 80% confluent, the cells were serum-starved overnight. In all cases, three wells were assigned per treatment.
The GnRH, Br, and buserelin were purchased from Sigma-Aldrich. DMEM was from Cambrex, and penicillin/streptomycin and fetal calf serum were both obtained from PAA Laboratories. PRL (NIDDK-oPRL-21, lot AFP10692C) was obtained from the National Hormone and Peptide Program. Rabbit monoclonal anti-phospho-STAT5 and anti-MAPK3/1 (ERK1/2) immunoglobulins were purchased from Cell Signaling Technology, and rabbit polyclonal anti-ACTIVE MAPK immunoglobulin was obtained from Promega Corp. Rabbit polyclonal anti-STAT5 and donkey anti-rabbit immunoglobulins were sourced from Santa Cruz Biotechnology, Inc. The bovine b-casein promoter and rat Lhb and Gapdh mRNA oligonucleotides were custom synthesized by Invitrogen and Sigma-Aldrich, respectively. Oligo(dT)18, DNase, reverse transcriptase, Faststart Taq DNA polymerase, and electrochemiluminescence (ECL) solution were all purchased from Roche Diagnostics. Phorbol-12-myristate-13-acetate (PMA), PD98059, AG490, and wortmannin (WORT) were from Tocris Bioscience. Bis-indolylmaleimide (BIS-1) was obtained from Calbiochem.
Experimental Design and Strategy
To assess the effects of PRL on basal and GnRH-stimulated LH synthesis and release and their subsequent modulation by DA, LbT2 cells were treated with 0, 5, 10, 50, 100, and 500 ng/ml of ovine PRL (oPRL) for 90 min under 1) control conditions (medium only), 2) 10 À7 M GnRH, 3) 10 À8 M Br, and 4) 10
À7
M GnRH plus 10 À8 M Br. Media were then collected and RNA extracted to allow quantification of LH concentrations and LHB mRNA expression. The dose range of PRL used extends from physiological to hyerprolactinemic concentrations. Hyperprolactinemia is characterized by serum PRL concentrations in excess of 100 ng/ml, and recent in vivo studies have shown that following secretion, pituitary peptides with molecular weights similar to that of growth factor (GH) are transiently trapped in the perivascular space before being coordinately released into the peripheral circulation [27] . Therefore, by virtue of this reservoir effect, hormones that are much larger than GH, such as PRL, would be sequestered in the perivascular space for a longer time and be active at very high concentrations because of the close association between gonadotrophs and the vasculature [28] . The optimal dose of GnRH and time of exposure required to stimulate both LH synthesis and release in the LbT2 gonadotroph have been previously determined [12] . A specific DRD2 agonist, Br was employed at a dose shown previously to induce a biological response in LbT2 gonadotrophs [11, 12] .
To determine interactions between the PRLR and GnRH receptor (GnRHR), buserelin, a GnRHR superagonist, was utilized. The application of 0.1 lM buserelin for 24 h has been shown previously to effectively downregulate the GnRHR [29] . Cells were assigned to one of the following treatment groups: 1) control (DMEM alone), 2) 500 ng/ml of oPRL, 3) 10 À7 M GnRH, 4) 500 ng/ml of PRL plus 0.1 lM buserelin, and 5) 10 À7 M GnRH plus 0.1 lM buserelin. When buserelin was utilized, cells were pretreated for 24 h before the addition of PRL or GnRH for 90 min. Media were then removed and concentrations of LH quantified by radioimmunoassay (RIA).
To investigate the effects of PRL and GnRH on STAT5 and MAPK (ERK) phosphorylation/activation, LbT2 cells were treated for 30 min with 0, 5, 10, 50, 100, and 500 ng/ml of PRL and assigned to receive either DMEM alone (control) or 10 À7 M GnRH. A 30-min treatment period with PRL has been shown previously to induce peak nuclear translocation of STAT5 in dopaminergic neurons [18] . Following treatment, cells were washed and proteins extracted using whole-cell extraction buffer (WCE; 50 mM Tris-HCl [pH 8], 150 mM NaCl, 0.5% NP40, 0.1 mM ethylenediaminetetra-acetic acid, 10 mM NaF, 1 mM Na 2 VO 3 , and 1 mM PMSF). Western blotting and immunoprecipitation were used to assess STAT5 and MAPK (ERK) phosphorylation.
To assess the functionality of the PKC pathway, cells were assigned to one of the following treatment groups: 1) control (DMEM alone), 2) 100 nM PMA (PKC agonist), and 3) 100 nM PMA plus 3 lM BIS-1 (PKC inhibitor). To assess the effects of JAK2, mitogen-activated protein kinase (MAP2K), PKC, and PIK3 inhibition upon the LH response to PRL, cells were assigned to one of the following groups: 1) control (DMEM alone), 2) 500 ng/ml of PRL, 3) 500 ng/ml of PRL plus 50 lM AG490 (JAK2 inhibitor), 4) 500 ng/ml of PRL plus 20 lM PD98059 (MAP2K inhibitor), 5) 500 ng/ml of PRL plus 10 lM WORT (PIK3 inhibitor), 6) 500 ng/ml of PRL plus 3 lM BIS-1, and 7) 100 nM PMA plus 50 lM AG490 plus 10 lM WORT. When inhibitors were utilized, cells were pretreated for 30 min at 378C before addition of the agonists, oPRL or PMA, for 90 min. Media were then collected and RNA extracted to allow quantification of LH concentrations and LHB mRNA expression using RIA and PCR, respectively. Optimal inhibitor and stimulant concentrations have been determined previously in LbT2 gonadotrophs [30] , aT3-1 gonadotrophs [31] , and hypothalamic cultures [18] .
LH RIA
The LH concentrations in culture media were determined by RIA [12] . The primary antibody employed was a rat LH antiserum (NIDDK-anti-rLH-S-11, lot AFPC697071P), with rat LH (AFP-11536B) for iodination and mouse LH (AFP-5306A) as standard. The minimal detectable LH concentration was 0.15 ng/ml, and the mean intra-and interassay coefficients of variation were 5.7% and 6.0%, respectively.
Polymerase Chain Reaction
Total RNA was extracted using the two-step guanidine thiocyanate-cyanate method [32] , and purity was assessed by determining absorbance at wavelengths of 260 and 280 nm. PCR for LHB mRNA was performed using a method previously described [12] . Briefly, two sets of primers were used: primers specific to the LHB-subunit (sense, 5
0 -GTCACAGGTCATTGGTT GAG-3 0 ; antisense, 5 0 -CTTCACCACCAGCATCTGTG-3 0 ), and primers specific to GAPDH (sense, 5 0 -GAACGGGAAGCTCACTGGCAT-3 0 ; antisense, 5
0 -GTCCACCACCCTGTTGCTGTAG-3 0 ). Primers for the constitutively expressed gene GAPDH were designed to span an intron to avoid amplification of genomic DNA and were used to confirm the integrity of the RNA and efficacy of the PCR. Three controls were run in parallel: 1) one in which water replaced the RNA, 2) one in which water replaced the RNA and reverse transcriptase was omitted, and 3) one in which RNA was used and reverse transcriptase was omitted.
Affinity Purification of Activated STAT5
The DNA-binding activity of STAT was assessed using a previously described affinity purification technique [17, 33] . Briefly, affinity purification for STAT5 was carried out by incubating whole-cell extract (protein concentrations equilibrated) with streptavidin agarose beads coupled to the STAT5 DNA-binding sequence of the bovine b-casein promoter (5 0 -AGATTTCTAGGAATTCAAATC-3 0 ) for 2 h at 48C. The mixture was then centrifuged at 6000 rpm for 4 min to collect the beads before washing in WCE. Next, the beads were heated at 958C for 10 min in SDS-loading buffer to denature and reduce the extracted STAT5 before centrifuging and retaining the supernatant. Purified samples were then subjected to Western blotting.
Western Blotting
Whole-cell extract was resolved using SDS-PAGE. For assessing phospho-STAT5 (pSTAT5), Hela cells treated with and without interferon-alpha were used as positive and negative controls, respectively. GnRH-treated LbT2 cells were used as positive control for phospho-MAPK3/1 (pMAPK3/1) [30] . Immunodetection was performed using rabbit immunoglobulins specific for pSTAT5 (both isoforms) and anti-ACTIVE MAPK. The membranes were then incubated in donkey anti-rabbit immunoglobulins linked to horseradish peroxidase, and the immunopositive protein bands were visualized using PROLACTIN ACTIONS IN THE GONADOTROPH 1047 ECL. The Western blots were then stripped before reprobing with rabbit immunoglobulins specific for total MAPK3/1 and STAT5 to control for unequal loading. The affinity-purified samples for activated STAT5 were subjected to electrophoresis in an identical manner, and immunodetection was performed with rabbit polyclonal immunoglobulins specific to total STAT5.
Quantification and Statistical Analyses
The PCR products were quantified using a previously validated method [12, 13] . Western blots were subjected to scanning densitometry, and the change in band density attributable to the application of GnRH was determined with respect to the relevant control band density in the same blot and expressed as percentage change versus control.
In all experiments, data normality was tested using the D'Agostino and Pearson omnibus test. All displayed values represent the mean 6 SEM of at least three experiments. The effects of PRL dose and treatment group on LH synthesis and release were assessed using two-way ANOVA. Because a significant (P , 0.01) dose 3 treatment interaction was detected, the effects of PRL dose on LH synthesis and release within each treatment group were subsequently assessed using one-way ANOVA. The effects of PRL and GnRH upon STAT5 and MAPK (ERK) phosphorylation and activation were examined using one-way ANOVA. Likewise, the effects of PMA, AG490, WORT, BIS-1, and buserelin upon the LH synthetic and secretory responses to PRL were assessed using one-way ANOVA. In all cases, Bonferroni and Newman-Keuls post hoc tests were used for pairwise comparisons.
RESULTS
PRL Stimulates LH Release and Dose-Dependently Modulates LH Secretory and mRNA Responses to GnRH
To assess the effects of PRL on gonadotroph output, the LH secretory and mRNA responses were measured using RIA and PCR following application of PRL in doses ranging from 0 to 500 ng/ml. PRL significantly stimulated LH release at concentrations of 50 ng/ml and higher (Fig. 1A, CON) . A clear dose response was observed, with 500 ng/ml of PRL stimulating a threefold increase in LH concentrations (0.28 6 0.04 vs. 0.86 6 0.07 ng/ml for 0 and 500 ng/ml of PRL, respectively; P , 0.001). The PRL-induced enhancement of LH release was similar to that observed when LbT2 cells were treated with GnRH alone (0.74 6 0.07 ng/ml for 10 À7 M GnRH), indicating that PRL is a potent LH secretagogue.
Prolactin modulated the LH response to GnRH in a biphasic manner (P , 0.01) (Fig. 1A, GnRH) . At a concentration of 50 ng/ml, PRL impaired the LH response to GnRH (0.5 6 0.04 ng/ml; P , 0.05), whereas at 500 ng/ml, PRL enhanced the LH response to the secretagogue (1.01 6 0.09 ng/ml; P , 0.05).
In contrast to LH secretion, PRL alone was unable to significantly alter LHB mRNA expression at all doses tested (Fig. 1B, CON) . In comparison, GnRH induced an almost twofold increase in LHB mRNA expression (179.7% 6 7.6% vs. 100.0% 6 23.6% for GnRH and control [medium only] at 0 ng/ml of PRL, respectively) (Fig. 1B, GnRH) . Notably, however, PRL completely suppressed the LHB mRNA response to GnRH at concentrations of 100 ng/ml and higher (P , 0.05) (Fig. 1B, GnRH) .
DA Does Not Affect LH Response to PRL but Suppresses PRL-Induced Biphasic Modulation of LH Response to GnRH
As previous studies have shown that high doses of PRL only suppress LH release when applied concomitantly with DA [8, 9, 12] , the modulatory effects of Br on the LH dose response to PRL were investigated. Br was unable to affect basal LH release or modify the stimulatory LH response to PRL (Fig.  1A, Br and CON) . In contrast, Br suppressed the bimodal LH response to GnRH induced by the presence of increasing doses of PRL (0.5 6 0.04 vs. 0.64 6 0.05 ng/ml at 50 ng/ml of PRL for GnRH alone and GnRH þ Br, respectively, and 1.01 6 0.09 vs. 0.43 6 0.04 ng/ml at 500 ng/ml of PRL for GnRH alone and GnRH þ Br, respectively; P , 0.01) (Fig. 1A , GnRH and GnRH þ Br).
When used alone, Br had no effect on LHB mRNA expression (Fig. 1B, Br) . However, as well as abolishing the LHB mRNA response to GnRH (100.5% 6 4.0% vs. 180.0% 6 7.6% for 10 À7 M GnRH in the presence or absence of Br, respectively; P , 0.01) (Fig. 1B , GnRH þ Br), Br allowed GnRH to increase LHB mRNA expression in the presence of PRL (164.2% 6 9.9% vs. 100.5% 6 4.0% for 50 and 0 ng/ml of PRL, respectively; P , 0.01) (Fig. 1B , GnRH þ Br).
GnRHR and PRLR Cooperation May Account for Interactions Between GnRH and PRL Axes
To exclude activation of signaling pathways coupled to the GnRHR as the mechanism involved in the stimulation of LH release by PRL, the ability of PRL to elicit LH release in the face of GnRHR downregulation was tested. When used alone, GnRH and PRL significantly stimulated LH release (0.62 6 0.03 and 0.93 6 0.05 ng/ml for 10 À7 M GnRH and 500 ng/ml of PRL, respectively, vs. 0.33 6 0.02 ng/ml for control; both P , 0.01) (Fig. 2) . Pretreatment with buserelin predictably reduced the LH response to GnRH (0.43 6 0.02 vs. 0.62 6 0.03 ng/ml for 10 À7 M GnRH in the presence or absence of 0.1 lM buserelin, respectively; P , 0.01). Unexpectedly, pretreatment with buserelin led to a significant enhancement of the LH response to PRL (0.93 6 0.05 vs. 1.11 6 0.06 ng/ml for 500 ng/ml of PRL alone and in combination with buserelin, respectively; P , 0.01).
PRL Does Not Signal Via the JAK/STAT Pathway in Gonadotrophs
Because PRL autoregulates its own release via short-loop feedback [14] , targeting DA neurons [34] where the PRLR is constitutively coupled to JAK2 and STAT5 [16, 18] , it was reasoned that PRL may also signal in gonadotrophs using similar pathways. Western blots probed for pSTAT5 failed to detect any immunopositive bands for all doses of PRL tested (Fig. 3A) . Hela cells treated with interferon-alpha, a cytokine known to phosphorylate STAT5 [35] , were strongly immunopositive for pSTAT5, indicating that the antibody and blotting methods employed were able to detect the resulting level of phosphorylation (Fig. 3A) . The immunopositive band corresponded to a molecular weight of approximately 90 kDa (i.e., within the range in which pSTAT5 is normally observed) [36] .
The inability to detect pSTAT5 in gonadotroph cells may have resulted from the relative insensitivity of Western blotting for lower levels of phosphorylation, so a highly sensitive affinity purification method was used to isolate activated STAT5 using a pull-down method with the consensus STAT5 DNA-binding sequence. With this method, DNA-binding activity was evident under control conditions (0 ng/ml of PRL) (Fig. 3) . However, irrespective of dose, PRL had no significant effect on the level of STAT5 DNA-binding (P . 0.91).
PRL Dose-Dependently Phosphorylates and Activates MAPK (ERK)
Having observed no changes in STAT5 phosphorylation/ activation, the effect of a dose range of PRL on MAPK (ERK) phosphorylation was then investigated. Western blotting with an antibody specific for pMAPK3/1 detected a faint, single, 42-1048 kDa band, corresponding to pMAPK3, under basal conditions (Fig. 4) . However, application of 500 ng/ml of PRL was unable to increase MAPK (ERK) phosphorylation over the time course tested (Fig. 4A) . Therefore, using a fixed exposure of 30 min, a time previously demonstrated to induce maximal MAPK (ERK) phosphorylation in human endometrial tissue [38] and aT3-1 gonadotrophs [38] , the effects of a range of PRL doses on MAPK (ERK) phosphorylation were examined. Whereas low doses of PRL induced a twofold increase in MAPK (ERK) phosphorylation (100% 6 10.64% vs. 204.1% 6 34.13% for 0 and 50 ng/ml of PRL, respectively; P , 0.01), 500 ng/ml of PRL were still unable to significantly alter phosphorylation (Fig. 4B) .
GnRH Does Not Stimulate STAT5 Signaling but Inverts MAPK (ERK) Response to PRL
Because JAK2 and SRC cooperatively activate STAT5 and, in the LbT2 cell line, GnRH upregulates SRC expression [39, 40] , the possibility that the presence of GnRH may lead to the amplification of PRL signaling through the JAK/STAT5 cascade was investigated. LbT2 cells were incubated with various doses of PRL in the presence of 10 À7 M GnRH. However, neither 10 À7 M GnRH nor increasing doses of PRL in the presence of 10 À7 M GnRH were able to evoke the phosphorylation of STAT5 (Fig. 5A) .
The stimulation of LHb glycoprotein expression in the LbT2 cells by GnRH has also been shown to depend on PKC- À7 M GnRH plus 10 À8 M Br. RIA and PCR were performed for the quantification of LH release (A) and LHB mRNA expression (B), respectively. Note in A that 1) PRL significantly increased basal LH secretion at concentrations of 50 ng/ml and higher under CON conditions, 2) PRL abolished the LH response to GnRH at a dose of 50 ng/ml and enhanced it at a dose of 500 ng/ ml, and 3) Br suppressed the LH response to GnRH alone and abolished the PRL-induced biphasic modulation of the LH response to GnRH. Note in B that 1) PRL had no effect on basal LHB mRNA expression, 2) the LHB mRNA response to GnRH was abolished by PRL concentrations of 100 ng/ml and higher, and 3) Br suppressed the LHB mRNA response to GnRH in the absence of PRL and allowed GnRH to stimulate LHB mRNA expression in the presence of 50 ng/ml of PRL. Three wells per dose of PRL were used in each treatment, and experiments were repeated three times. Values represent the mean 6 SEM for each dose of PRL. *P , 0.05 and **P , 0.01 versus CON, #P , 0.01 versus GnRH.
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induced MAPK3 phosphorylation [30] . Therefore, the convergence of the GnRH and PRL axes at the level of MAPK (ERK) was investigated. GnRH induced phosphorylation of MAPK3 (629% 6 60.0% vs. 100% 6 44.3% for GnRH and negative control, respectively) (Fig. 5B) , and this response was biphasically modulated by increasing doses of PRL. Indeed, 50 ng/ml of PRL resulted in a significant suppression of the MAPK (ERK) response to GnRH (335.0% 6 60.9% vs. 629% 6 60.0% for 50 and 0 ng/ml of PRL, respectively; P , 0.001), an effect that was not detected at 500 ng/ml of PRL (Fig. 5B) . Therefore, the biphasic MAPK (ERK) response to PRL alone (Fig. 4B) was inverted by the presence of GnRH (Fig. 5B) .
PRL Enhances LH Secretion in LbT2 Gonadotrophs in a JAK2-PI3-PKC-Dependent Manner
Because high doses of PRL were unable to activate the STAT5 and MAPK cascades, we investigated whether the constitutive association of the PRLR with JAK2 could lead to the activation of alternative LH-releasing pathways, such as PIK3 and PKC. Confirming that PKC was able to induce LH release in the LbT2 gonadotroph, PMA, a potent and specific activator of PKC, significantly enhanced LH release over control conditions (0.98 6 0.07 vs. 0.44 6 0.07 ng/ml for 100 nM PMA and control, respectively; P , 0.01) (Fig. 6A) . In
FIG. 2. Effects of GnRHR desensitization on the LH response to PRL.
Cells were assigned to one of the following treatment groups: mediumalone (control [CON]), 500 ng/ml of oPRL, 10 À7 M GnRH, 500 ng/ml of oPRL plus 0.1 lM buserelin, or 10 À7 M GnRH plus 0.1 lM buserelin. When buserelin was utilized, cells were pretreated for 24 h before the addition of the PRL or GnRH for 90 min. Media were retained and RIA performed to quantify concentrations of LH. Note that GnRH and PRL both stimulated LH release and that buserelin abolished the LH response to GnRH but enhanced the LH response to PRL. Values represent the mean 6 SEM for each treatment.
FIG. 3. Effects of PRL on activation of STAT5.
A) LbT2 cells were treated with 0, 5, 10, 50, 100, and 500 ng/ml of oPRL for 30 min before protein extraction. Phosphorylation of STAT5 was subsequently detected using Western blotting. The blot was stripped and reprobed for total STAT5 to determine the accuracy of protein loading. Positive (þ) and negative (À) controls (Hela cells treated and untreated with interferon-alpha, respectively) were used to validate antibody specificity. Note that PRL did not phosphorylate STAT5. B) LbT2 cells were treated in a manner identical to that described in A. The resulting cell lysates were affinity-purified for activated STAT5 using streptavidin-agarose beads containing the STAT5 consensus DNA-binding domain before being subjected to Western blotting. Densitometric analysis of the blots confirmed that PRL was unable to significantly affect the DNA-binding activity of STAT5 at all doses tested. All blots are representative of three independent experiments. Values represent the mean 6 SEM. NS, nonsignificant.
FIG. 4. Effects of PRL on phosphorylation of MAPK (ERK).
A) LbT2 cells were treated with 500 ng/ml of oPRL for 0, 5, 10, 30, and 60 min, and phosphorylation of MAPK3/1 (pMAPK) was detected using Western blotting. The blot was stripped and reprobed for total MAPK (ERK) to determine the accuracy of protein loading. Positive controls (GnRHstimulated LbT2 gonadotroph cells) were loaded to validate antibody specificity. B) LbT2 cells were treated for 30 min with 0, 5, 10, 50, 100, and 500 ng/ml of PRL before the extraction of protein and Western blotting as above. Densitometric analysis of the blots revealed a dosedependent induction of MAPK3 phosphorylation by PRL. The blot is representative of three independent experiments. Values represent the mean 6 SEM. agreement with these findings, BIS-1, a potent inhibitor of PKC, reduced the LH response to PMA (0.61 6 0.06 vs. 0.98 6 0.07 ng/ml for 3 lM BIS-1 þ 100 nM PMA and for 100 nM PMA, respectively; P , 0.01) (Fig. 6A) . Similarly, PMA significantly increased LHB mRNA expression by 60% over control values (P , 0.01) (Fig. 6B) . This response was abolished by BIS-1 (P , 0.01), confirming the ability of the PKC signaling pathway to enhance LH synthesis in this cell type. As anticipated, the application of BIS-1 had no effect on LHB mRNA expression when applied concurrently with PRL (Fig. 6B) .
FIG. 5. Effects of GnRH on the ability of PRL to phosphorylate STAT5 and MAPK (ERK).
A) LbT2 cells were treated with 0, 5, 10, 50, 100, and 500 ng/ml of oPRL for 30 min in the presence of 10 À7 M GnRH before protein extraction for detection of phosphorylated and total STAT5 by Western blotting. Note that PRL did not gain the ability to phosphorylate STAT5 following the application of GnRH. B) LbT2 cells were treated for 30 min with 0, 5, 10, 50, 100, and 500 ng/ml of PRL in the presence of 10 À7 M GnRH, and phosphorylated MAPK3/1 (pMAPK) and total MAPK (ERK) were detected using Western blotting. Note that GnRH was able to invert the biphasic effect of PRL on MAPK (ERK) phosphorylation (shown in Fig.  4B ). GnRH treated (þ) and untreated (À) controls were loaded to validate the specificity of the antibodies employed. All blots are representative of three independent experiments. Values represent the mean 6 SEM. "   FIG. 6 . Role of PKC in LH synthesis and release and effects of inhibition of JAK2, PIK3, and PKC on the LH secretory response to PRL. A) LbT2 gonadotroph cells were treated with medium alone (control [CON] ), 500 ng/ml of oPRL, 500 ng/ml of oPRL plus 3 lM BIS-1, 100 nM PMA, or 100 nM PMA plus 3 lM BIS-1. Cells in the PRL plus BIS-1 and the PMA plus BIS-1 groups were preincubated with 3 lM BIS-1 for 30 min before the application of treatments for 90 min. Media were removed and LH concentrations determined by RIA. Note that PMA significantly increased LH release, an effect that was abolished by the concomitant application of BIS-1. B) LbT2 gonadotroph cells were treated with medium alone (control [CON]), 500 ng/ml of oPRL, 500 ng/ml of oPRL plus 3 lM BIS-1, 100 nM PMA, and 100 nM PMA plus 3 lM BIS-1. Cells in the PRL plus BIS-1 and the PMA plus BIS-1 groups were preincubated with 3 lM BIS-1 for 30 min before the application of treatments for 90 min. RNA was extracted, and PCR for LHB mRNA expression was performed. Note that PRL had no significant effect on LHB mRNA expression, whereas PMA significantly increased LHB mRNA, an effect that was abolished by the concomitant application of BIS-1. C) LbT2 cells were pretreated with AG490 (JAK2 inhibitor), WORT (PIK3 inhibitor), BIS-1 (PKC inhibitor), or PD98059 (MAPK inhibitor) for 15 min before the application of PRL or were pretreated with AG490 and WORT in combination for 15 min before the application of PMA. Note that the PRL-induced stimulation of LH release was abolished by the application of AG490, WORT, and BIS-1, but not by PD98059. The application of AG490 plus WORT had no effect on the LH response to PMA. In all panels, values represent the mean 6 SEM for each treatment. Experiments were repeated at least three times.
To test whether the PRLR was coupled to PKC, we used a range of signaling pathway inhibitors. The LH secretory response to 500 ng/ml of PRL was abolished by the individual applications of AG490 (0.32 6 0.03 ng/ml, P , 0.001), WORT (0.31 6 0.04 ng/ml, P , 0.001), and BIS-1 (0.27 6 0.03 ng/ml, P , 0.001), which are specific inhibitors of JAK2, PIK3, and PKC, respectively (Fig. 6C) . PD98059, a specific MAP2K inhibitor, failed to significantly alter the LH response to PRL. Finally, the stimulation of LH release by a PKC agonist (PMA) was unaffected by the addition of PIK3 (WORT) and JAK2 (AG490) antagonists, confirming that PKC was the convergence point for the upstream PIK3 and JAK2 pathways, as opposed to a distinct LH-releasing pathway that could be activated by PRL alongside the activation of the MAPK cascade (Fig. 6C) . The solvents used to dilute the various signaling inhibitors did not affect the ability of PRL to stimulate LH release (data not shown).
DISCUSSION
The present results demonstrate that PRL acts as a powerful secretagogue of LH from gonadotroph cells and that this stimulatory effect is mediated by a JAK2-PIK3-PKC-dependent signaling cascade. Interestingly, PRL modulated the LH secretory response to GnRH in a biphasic manner, an effect that was abolished by the presence of the DA agonist, Br. In contrast to the results concerning hormone release, PRL was unable to stimulate LHB mRNA expression and dosedependently suppressed the LHB mRNA response to GnRH. Further experiments highlighted that the suppressive action of PRL on the LH responses to GnRH was mediated, at least in part, by MAPK. Intriguingly, the inclusion of Br modified the suppressive effects of PRL on the LHB mRNA response to the decapeptide and allowed GnRH to increase LHB mRNA expression in the presence of PRL. These data extend our previous findings using primary pituitary cultures and LbT2 gonadotroph cultures [8, 9, 12] ; taken together, these data indicate that the actions of PRL within the gonadotroph likely play a crucial role in the intrapituitary regulation of fertility.
Given the inability of PRL to affect LHB mRNA and the role of MAPK (ERK) in gene transcription, the dose-dependent effect of PRL on phosphorylation was unexpected. In the liver, PRL is known to increase hepatocyte mitosis, an effect that likely is mediated by MAPK (ERK) [23, 41] . Therefore, the maximal activation of MAPK (ERK) observed in the present study at 50 ng/ml of PRL could have reflected an effect of relatively low doses of PRL on gonadotroph growth and differentiation. In light of this, the role of a pathway that could preferentially stimulate LH release in the absence of changes in RNA synthesis was investigated. Treatment with PMA, a specific agonist of PKC, potently stimulated LH release, demonstrating that PKC is functional in the LbT2 gonadotroph. Indeed, pretreatment of cells with BIS-1, a specific PKC inhibitor, completely abolished the LH response to PRL and reduced LH concentrations to basal levels, confirming that PKC is essential for the stimulation of LH release by PRL.
The upstream signaling mechanisms responsible for the activation of PKC by PRL are not known, because the PRLR is not coupled to regular PKC-activating pathways, such as phospholipase-C (PLC) [42] . In neutrophils, however, the granulocyte-macrophage colony-stimulating factor receptor, a member of the cytokine receptor superfamily, activates PIK3 through tyrosine phosphorylation by JAK2 [43] . Products generated by PIK3, such as PtdIns-3,4-P2 and PtdIns-3,4,5-P3, activate the PKC isoforms PRKCD, PRKCE, and PRKCH [44] . In our experiments, PRL was unable to elicit LH release in the presence of specific inhibitors of JAK2 and PIK3. To account for the activation of alternative downstream pathways by JAK2 and PIK3, which were unrelated to the activation of PKC by PRL and which may have affected LH release, PKC was directly activated by PMA in the presence of both JAK2 and PIK3 inhibitors. As expected, PMA was still able to stimulate the release of LH.
Cell lines generated using SV40-induced oncogenesis have been shown to dedifferentiate following multiple passages, resulting in loss of cell properties [45] . This limitation was not associated with the present work, because LH secretion, a parameter that is particularly vulnerable to dedifferentiation [46] , was maintained at a stable level during the study. Because the magnitudes of the LH responses to PRL and GnRH were similar, the role of PRL in GnRHR activation was investigated. Upon persistent stimulation with GnRH, the GnRHR undergoes desensitization and internalization [47] . However, although pretreatment of LbT2 cells with buserelin, a potent GnRHR agonist, was able to block the LH response to GnRH, as expected, it also subtly enhanced the LH response to PRL. Whereas GnRH is known to cause PRL release from pituitary cultures [48] , to our knowledge a direct interaction between the PRLR and GnRHR in the same cell type has not been reported until now. In the LbT2 gonadotroph, PRKCD and PRKCE specifically couple the GnRHR to cAMP, and a specific downregulation of both isoforms has been observed in the LbT2 cell line following chronic application of GnRH [49] . It is unlikely that PRL signaling via PKC is dependent on either of these isoforms, because the application of buserelin slightly, but significantly, enhanced the LH response to PRL. Thus, PRL may signal using a novel PKC isoform as an alternative to those activated by GnRH, such as PRKCH which is still activated by the products of PIK3 [50] . The enhancement of the LH response to PRL following GnRHR downregulation with buserelin may result from removal of the inhibitory effects of PRKCD/E on other novel PKC isoforms. Indeed, it has been demonstrated that in muscle and adipose cells, activation of PRKCB is responsible for restraining the activation of PRKCZ by insulin [51] .
The physiological relevance of the potent LH-releasing activity of PRL at the level of the gonadotroph is not clear, because this effect is not observed in gonadotrophs when they remain within their tissue context exposed to GnRH and DA and to the paracrine influences of other cells, which modify the nature of the response. Indeed, in situ, cell-cell interactions likely mask this action of PRL. In this regard, we have observed that coculture of gonadotrophs with folliculostellate cells results in the suppression of PRL-induced LH release in a juxtacrine manner [52] . The identification of the intrinsic characteristics of these cell-cell interactions is of particular interest, because their blockade may provide a novel method with which to unmask the LH-releasing effect of PRL in vivo and prevent infertility resulting from hyperprolactinemia. Unlike PRL, GnRH was able to upregulate both LHB mRNA expression and LH release. This was not surprising, given that GnRH increases LH glycoprotein expression in the LbT2 gonadotroph in a PKC-MAPK (ERK)-dependent manner. Interestingly, PRL suppressed both the LH synthetic and secretory responses to GnRH at a dose of 50 ng/ml. This effect likely involves MAPK (ERK), because at that dose, PRL was able to markedly suppress GnRH-induced MAPK (ERK) phosphorylation. In contrast, 500 ng/ml of PRL enhanced the LH secretory response to GnRH; this coincided with the inability of PRL to suppress GnRH-induced MAPK (ERK) phosphorylation. Therefore, at high doses of PRL, the activation of PKC by GnRH is likely amplified, resulting in 1052 enhanced LH release. The magnitude of increase in LH release may not have equated to the sum of that observed when both ligands were added independently because of the restraining effect of the PKC isoforms activated by GnRH on those activated by PRL. In contrast to effects on hormone release, 500 ng/ml of PRL continued to suppress the LHB mRNA response to GnRH. This was somewhat puzzling, as at this dose, PRL only suppressed GnRH-induced MAPK (ERK) phosphorylation by 20%. Nevertheless, this may still be adequate to allow suppression of the LHB mRNA response to the decapeptide.
The ability of Br to abolish the PRL-induced biphasic modulation of the LH secretory response to GnRH confirms the requirement for the presence of DA in the suppression of the LH response to GnRH by high doses of PRL. We previously documented this phenomenon in primary pituitary cultures from two seasonally breeding mammalian species [8, 9] . In gonadotrophs, DA acts through the DRD2, a G protein-coupled receptor that negatively regulates adenylyl cyclase, leading to the inhibition of cAMP accumulation and the retention of PKC and PKA in their inactive states [53] . Therefore, DA must prevent both the upregulation of PKC by GnRH as well as the enhancement of this PKC activation by PRL. Intriguingly, the abolition of PKC activity by DA requires interactions between the GnRHR and DRD2, because Br was unable to affect the stimulation of LH release by PRL, a response that is mediated by PKC. Similar mechanisms must also have accounted for the ability of DA to suppress the LHB mRNA response to GnRH; indeed, the stimulation of LHB mRNA synthesis is dependent on a PKC-MAPK (ERK) signaling process. Interestingly, the inclusion of DA modified the suppressive effects of PRL on the LHB mRNA response to GnRH and allowed GnRH to increase LHB mRNA expression in the presence of PRL. The signaling pathways that account for this are unlikely to involve upregulation of MAPK (ERK) or PKC activity, because DA was unable to activate MAPK (ERK) in the closely related aT3-1 gonadotroph cell line [13] and DA suppresses PKC activity [53] . However, DA is known to activate adenylyl cyclase-activating polypeptide, which is able to alter gonadotropin a-subunit through the activation of MAPK3/1 and PKA [54] . Therefore, signaling pathway overlap between PKA, PKC, and MAPK (ERK) may account for the complex interactions observed between the dopaminergic, PRL, and GnRH axes. A working model for the cell-signaling cascade underlying PRL-induced stimulation of LH release from gonadotrophs and interactions with signaling pathways evoked by activation of GnRHR and DRD2 is presented in Figure 7 .
The physiological implications of these findings could be relevant to the control of human fertility. Indeed, during lactation, the combined suppressive effects of PRL and DA may be important for maintaining amenorrhea. Although the feedback effects of PRL on the activity of DA neurons is downregulated at this stage [55] , a strong residual dopaminergic tone is still present, because treatment of lactating women with DA antagonists markedly increases PRL secretion [56] . In addition, evidence suggests that the pituitary gland may itself be an important source of DA [57] . Furthermore, the peak area of LH output is reduced during lactational amenorrhea, whereas the pulse frequency is unaffected, consistent with a decrease in the amount of GnRH released per pulse and/or a decrease in pituitary responsiveness to available GnRH [58] . Therefore, PRL and DA may play an important role in suppressing the gonadotroph response to GnRH pulses during lactation, thus decreasing the amount of LH released.
In conclusion, we report the potent stimulation of LH release by a range of PRL doses in a homogeneous population of gonadotrophs. This effect is not mediated by the STAT5 or MAPK pathways but, rather, by PKC. Furthermore, the activation of PKC is dependent on the upstream activation of JAK2 and PIK3. The dose-dependent modulation of the LH synthetic and secretory responses to GnRH by PRL and its abolition by DA highlight the importance of the interactions between the GnRH, PRL, and dopaminergic axes in the control of fertility. Together, these data provide a full and novel characterization of PRL signaling in the gonadotroph, and they verify that intrapituitary mechanisms are both clearly important with respect to infertility caused by hyperprolactinemia and far more complex than originally envisaged.
